Hyperthermia Systemic
description
Transcript of Hyperthermia Systemic
HYPERTHERMIA, SYSTEMIC
R. WANDA ROWE-HORWEGE
University of Texas MedicalSchoolHouston, Texas
INTRODUCTION
Systemic hyperthermia is deliberate heating of the wholebody to achieve an elevated core temperature for thera-peutic purposes. Other terms used are whole-bodyhyperthermia, systemic or whole body thermal therapy,and hyperpyrexia. The goal of systemic hyperthermia is toreproduce the beneficial effects of fever. Typically, corebody temperatures of 41–42 8C are induced for 1–2 h, oralternatively 39–40 8C for 4–8 h. Systemic hyperthermia,by virtue of application to the whole body, aims to alleviatesystemic disease conditions, in contrast to local or regionalhyperthermia that treats only a specific tissue, limb, orbody region.
HISTORICAL BACKGROUND
The use of heat to treat disease goes back to ancient times.Application of fire to cure a breast tumor is recorded in anancient Egyptian papyrus, and the therapeutic value ofelevated body temperature in the form of fever was appre-ciated by ancient Greek physicians. Hippocrates wrote,‘‘What medicines do not heal, the lance will; what thelance does not heal, fire will,’’ while Parmenides stated,
‘‘Give me a chance to create a fever and I will cure anydisease.’’ In the first century AD, Rufus (also written asRefus or Ruphos) of Ephesus advocated fever therapy fora variety of diseases. Hot baths were considered thera-peutic in ancient Egypt, Greece, Rome, China, and Indiaas they still are in many aboriginal cultures today, alongwith burying diseased individuals in hot sand or mud.Hot baths and saunas are an integral part of healthtraditions throughout the Orient, in Indian Ayurvedicmedicine, as well as in Eastern European and Scandina-vian countries. Following several earlier anecdotalreports, several nineteenth century German physiciansobserved regression or cure of sarcoma in patients whosuffered prolonged, high fevers due to infectious diseases.This led to efforts to induce infectious fevers in cancerpatients, for example, by applying soiled bandages or theblood of malaria patients to wounds. The late nineteenthcentury New York physician, William Coley, achievedcancer cures by administration of erysipelas and otherbacterial endotoxins, now known as Coley’s toxins, andattempted to create standardized preparations of thesepyrogens (1). At around the same time, treatment ofsyphilis by placing the patient in a stove-heated room,or a heat box, became commonplace. Successful hyperther-mic treatment of other sexually transmitted diseases, suchas gonorrhea, and neurological conditions, such as choreaminor, dementia paralytica, and multiple sclerosis alongwith arthritis, and asthma were widely reported. Interest-ingly, it was noted by Italian physicians that upon comple-tion of the draining of the Pontine Swamps near Rome byMussolini in the 1930s, not only was malaria eradicated,but the prevalence of cancer in the area was the same as inthe rest of Italy, whereas earlier the whole malaria-infected region was noted for its absence of cancer. Itwas concluded that the frequent fever attacks commonin malaria stimulated the immune system to prevent thedevelopment of cancers.
The science of hyperthermia became grounded in thefirst few decades of the twentieth century when some of thebiological effects of elevated body temperature were eluci-dated and attempts were made to understand and controlthe therapeutic application of heat. Numerous deviceswere developed to produce elevated temperatures of thebody, by a variety of physical means. After a shift in focus tolocal and regional hyperthermia, there is now a resurgenceof interest in systemic hyperthermia for treatment of cancer,as well as other systemic diseases. Whole-body hyperther-mia treatment is now carried out at several universitycenters in the United States, and Europe (Table 1), wherecontrolled clinical trials are being carried out. Numerousprivate clinics, principally in North America, Germany,Austria, Eastern Europe, Japan, and China also performsystemic hyperthermia, mostly as part of holistic, alterna-tive, treatment regimens.
PHYSICS OF SYSTEMIC HYPERTHERMIA
As shown schematically in Fig. 1, in order to achieve bodytemperature elevation, there must be greater depositionof heat energy in the body than heat energy lost from
42 HYPERTHERMIA, SYSTEMIC
Encyclopedia of Medical Devices and Instrumentation, Second Edition, edited by John G. WebsterCopyright # 2006 John Wiley & Sons, Inc.
Ta
ble
1.
Cli
nic
al
Aca
dem
ic/R
eg
ion
al
Sy
stem
icH
yp
erth
erm
iaC
en
ters
Cou
ntr
yC
ity
Inst
itu
tion
Pri
nci
pal
Inves
tigato
rH
eat
Typ
e,M
ach
inea
Pro
toco
l(t
ime,
tem
p)
Asi
aC
hin
aB
aod
ing
Sec
ond
Hos
pit
al
ofB
aod
ing
Ch
un
zhu
Yin
RF
3.5
–6
h,
40–40.5
8CC
hin
aC
han
gch
un
Jil
inT
um
orH
osp
ital
Ch
an
ggu
oH
ong
RF
3.5
–6
h,
40–40.5
8CC
hin
aJia
ngm
enG
uan
gd
ong
Jia
ngm
enR
enm
inH
osp
ital
Wen
pin
gW
uIR
Ch
ina
Sh
an
gh
ai
Ch
an
gh
ai
Hos
pit
al,
Sec
ond
Mil
itary
Med
ical
Sch
ool
Yaji
eW
an
gC
hin
aS
han
gh
ai
Dep
art
men
tof
Tu
mor
Hyp
erth
erm
iaC
ente
rK
ai-
shen
gH
ouIR
,E
T-S
pace
extr
aco
rpor
eal
1–2
h,
41.8
–42.5
8C
Ch
ina
Sh
an
gh
ai
Sh
an
gh
ai
Jin
gan
Cen
tral
Hos
pit
al
Wei
pin
gT
ao
IR,
ET
-Sp
ace
extr
aco
rpor
eal
2h
,41.6
8C4
h,
42.1
8C
Ch
ina
Tai’an
Cit
y88th
Hos
pit
al
ofP
LA
Yon
gP
eng
1–2
h,
41.8
8C6
h,
39.5
–408C
Ch
ina
Zh
engzh
ouM
oder
nH
osp
ital,
Zh
engzh
ouD
ingji
uL
iR
F3.5
–6
h,
40–40.5
8CJap
an
Tok
yo
Lu
ke
Hos
pit
al
Ak
ira
Tak
euch
iIR
Eu
rop
eB
elaru
sM
insk
Bel
aru
sC
ente
rfo
rP
edia
tric
On
colo
gy
an
dH
emato
logy
Rei
man
nIs
-zad
eH
FE
M,
Yak
hta
-52
h,
41.8
–42.5
8C1
h,
42.5
–438C
Ger
man
yB
erli
nL
ud
wig
Maxim
ilia
nU
niv
ersi
tyC
hari
teM
edic
al
Cen
ter
Ber
tH
ild
ebra
nd
t,H
an
no
Rie
ss,
Pet
erW
ust
IR,
Irath
erm
1h
,41.8
8C
Ger
man
yF
ran
kfu
rtK
ran
ken
hau
sN
ord
wes
tE
lke
Jager
,A
kin
Atm
ata
IR,
Aqu
ath
erm
1h
,41.8
8CG
erm
an
yM
un
ich
Lu
dw
igM
axim
ilia
nU
niv
ersi
tyH
osp
ital
Cli
nic
Hara
ldS
omm
erIR
,Ir
ath
erm
1h
,41.8
8CH
un
gary
Kec
skem
etIn
stit
ute
ofR
ad
iolo
gy
ofK
ecsk
emet
Mik
los
Szu
csIR
,O
nco
Th
erm
1h
,41.8
8CN
orw
ay
Ber
gen
Un
iver
sity
ofB
ergen
,H
au
kel
an
dU
niv
ersi
tyH
osp
ital
Baard
-Ch
rist
ian
Sch
emIR
,Ir
ath
erm
1h
,41.8
8CR
uss
iaN
ovos
ibir
skS
iber
ian
Sci
enti
fic
Res
earc
hIn
stit
ute
ofH
yp
erth
erm
iaR
oman
Tch
ervov
Wate
rbath
43.5
–44.0
8CR
uss
iaO
bn
insk
Med
ical
Rad
iolo
gic
al
Res
earc
hC
ente
rof
Ru
ssia
nA
cad
emy
ofM
edic
al
Sci
ence
s,O
bn
insk
Yu
riM
ard
yn
sky
HF
EM
,Y
ak
hta
51–2
h,
41.0
–42.3
8C
Nort
hA
mer
ica
Un
ited
Sta
tes
Galv
esto
n,
TX
Un
iver
sity
ofT
exas
Med
ical
Bra
nch
Jos
eph
Zw
isch
enber
ger
extr
aco
rpor
eal
2h
,42.5
8CU
nit
edS
tate
sH
oust
on,
TX
Un
iver
sity
ofT
exas
Med
ical
Sch
ool
Joa
nM
.B
ull
IR,
Hec
kel
6h
,408C
Un
ited
Sta
tes
Bu
ffalo
,N
YR
osw
ell
Park
Can
cer
Inst
itu
teW
illi
am
G.
Kra
ybil
lIR
,H
eck
el6
h,
408C
Un
ited
Sta
tes
Du
rham
,N
CD
uk
eC
omp
reh
ensi
ve
Can
cer
Cen
terb
Zel
jko
Vu
jask
ovic
IR,
Hec
kel
6h
,408C
aR
ad
iofr
equ
ency
¼R
F;
infr
are
d¼
IR.
bS
tart
ing
in2006.
43
conduction, convection, radiation and evaporation, that is,
Q0depDt>Q0
lossDt ð1Þ
where Q0 ¼ DQ/Dt represents the change in heat energy,Q (measured in Joules or calories), over a time periodDt. Net heat energy deposition in a volume element DVof tissue of density rtis results in an increase in tem-perature DT dependent on the specific heat of the tissue,ctis,
Q0dep
DV�
Q0loss
DV
!Dt ¼ ðrtisDVÞctisDT
DT ¼ ðQ0dep � Q0
lossÞ Dt
rtisctisð2Þ
Heat deposition is the sum of the absorbed power den-sity, Pabs, from external sources and heat generated bymetabolism, Qmet,
DQ0dep
DV¼ Pabsðx; y; z; tÞ þ
DQ0met
DVðx; y; z; tÞ ð3Þ
If the air temperature is higher than the body surfacetemperature, heat is absorbed from air surrounding thebody by the skin, as well as during respiration. Powerdeposition in tissue from external electromagnetic fieldsdepends on the coupling of the radiation field (micro-wave, RF, ultrasound, visible or IR light) with tissue.The body’s metabolic rate depends on the amount ofmuscular activity, the temperature, pressure andhumidity of the environment, and the size of the body.Metabolic rate increases nonlinearly with core bodytemperature, in part due to the exponential increaseof the rate of chemical reactions with temperature(Arrhenius equation). An empirical relationship between
basal metabolic rate and core temperature has beendetermined as
Basal MR ¼ 85 � 1:07ðTcoreÞ
0:5ð4Þ
whichcanbeexploited tomaintainelevatedbodytemperatures(2). At room temperature a human body produces � 84 W,which increases to �162 W at a core temperature of 41.8 8C.
Heat losses from the body are often termed sensible(convective, conductive, radiative) and insensible (evapora-tive, latent). The primary mode of heat loss from the body isby radiation, as described by the Stefan–Boltzmann law,
Q0rad
DV¼ eskinsAskinðTskin � TsÞ4 ð5Þ
where Q0rad/DV is the power radiated, eskin is the emissivity
of the skin (radiating material), s is Stefan’s con-stant ¼ 5.6703 � 10�8 Wm�2/K, Askin is the skin surfacearea, Tskin is the temperature of the skin (radiator), and Ts
is the temperature of the surroundings (e.g., air, water,wax). Human skin is a near perfect radiator in the IR, withan emissivity of 0.97. At room temperature, >50% of theheat generated by metabolism is lost by radiation; a clothedadult loses some 50 W at room temperature. This increasesto �66% at a core temperature of 41.8 8C, as is targeted in anumber of systemic hyperthermia protocols, when the skintemperature rises to 39–40 8C (3).
Direct transfer of body heat to the molecules around thebody (typically air) occurs by conduction, or molecularagitation within a material without any motion of thematerial as a whole, which is described by Fourier’s law,
DQ0cond
DV¼ kAskin
DT
Dxð6Þ
where DQcond is the heat energy transferred per unitvolume in time Dt, k is the thermal conductivity (WmK�1)of the material surrounding the body (air, water), and DT isthe temperature difference across thickness Dx of thematerial. Air is a poor thermal conductor, therefore heatloss by conduction is relatively low. On the other hand,water has a thermal conductivity 20 times that of air at0 8C, increasing further with temperature, therefore dur-ing hyperthermia it is important that any water in contactwith the skin is not at a lower temperature. The relativethermal conductivity of body tissues is important in deter-mining thermal conduction within the body from externalsources of heat. For example, fat is a relative thermalinsulator with a thermal conductivity one third of that ofmost other tissues, therefore fat bodies are slower to heat.
Convective heat transfer involves material movementand occurs principally via blood moving heat to, or from,the skin and other tissues, and air currents (respiratoryand environmental) moving warm air to or from the body.Equation 7 is written for the blood,
DQ0conv
DV¼ rbcb½wbðx; y; z;TÞ ðT � TbÞ þ Ubðx; y; z;TÞ rT�
ð7Þ
where wb is the specific capillary blood flow rate, Ub is thespecific blood flow through other vessels. In the context of
44 HYPERTHERMIA, SYSTEMIC
Figure 1. Schematic of heat balance mechanisms in the humanbody. Body temperature is determined by the balance of metabolicheat production plus heating from external sources, and heatlosses by radiation, evaporation, convection, and conduction.
systemic hyperthermia, where a patient is in a closedchamber, environmental air currents can be minimized.Heat loss by respiration, however, can amount to almost10% of metabolic heat generation.
Another route of heat loss from the body is evaporationof perspiration from the skin. Because of the very largeheat of vaporization of water, cooling of the blood in skincapillaries occurs due to evaporation of sweat. Evaporationfrom exhaled moisture also results in cooling of the sur-rounding air.
DQ0evap
DV¼ mw
Lv
Dtð8Þ
where mw is the mass of the water and Lv is the latent heatof vaporization (2.4 � 106 Jkg�1 at 34 8C). In hot condi-tions with maximal rates of evaporation, heat loss throughevaporation of sweat can be as much as 1100 W. Heat lossin the lungs is �10 W.
Combining the heat generation and heat loss termsleads to a general heat transfer equation, an extensionof the classic Pennes bioheat transfer equation.
DQ0met
DVþ Pabs
� ��
�DQ0
rad
DVþDQ0
cond
DVþ DQ0
conv
DVþDQ0
resp
DVþDQ0
evap
DV
� ��¼ rtisctisDT ð9Þ()
into which the expressions given in Eqs. 2–8 may be sub-stituted. Precise solution of this equation for temperaturedistribution is complex and requires a number of simplifyingassumptions which have generated significant controversyin bioheat transfer circles. Modeling of temperature distri-butions within a body subjected to hyperthermia is alsocomplex because of the heterogeneity of thermal character-istics between and within tissue, the directionality of powerapplication, and the dynamic nature of thermoregulation byhuman body. Nonetheless, the factors governing systemicheating of the body can be appreciated.
INDUCTION OF SYSTEMIC HYPERTHERMIA
Apart from the induction of biological fever by pathogens ortoxins, all methods of hyperthermia involve transfer ofheat into the body from an external energy source. Therequired net power to raise the temperature of a 70 kghuman from 37 to 41.8 8C (2) is 400 W (5.7 mW). While theheat absorption from these sources is highly nonuniform,distribution of thermal energy by the vascular systemquickly results in a uniform distribution of temperature.Indeed, systemic hyperthermia is the only way to achieveuniform heating of tissues. Because physiological thermo-regulation mechanisms such as vasodilation and perspira-tion counteract attempts to increase core body temperature,careful attention must be paid to optimizing the physicalconditions for heating such that there is efficient depositionof heat energy in the body and, even more importantly,minimization of heat losses. Wrapping the body in reflectiveblankets, foil, or plastic film to reduce radiative and eva-porative losses, or keeping the surrounding air moist to
minimize losses by perspiration are key techniques forachieving a sustained increase in body temperature.
Noninvasive methods of heating include immersing thebody in hot water or wax, wrapping the body in a blanket orsuit through which heated water is pumped, placing thepatient on a heated water mattress, surrounding the bodywith hot air, irradiating with IR energy, and applying RFor microwave electromagnetic energy. These techniquesmay be applied singly or in combination. For example, thePomp–Siemens cabinet used until recently throughoutEurope, as well as in the United States, a modificationof a device originally developed by Siemens in the 1930s,has the patient lying on a heated water mattress underwhich an inductive loop generates an RF field, all inside achamber through which hot air is circulated. The RussianYakhta-5 system applies a high frequency (13.56 MHz)electromagnetic field through a water-filled mattress topermit whole body heating up to 43.5 8C and simultaneousdeep local hyperthermia through additional applicators pro-viding 40.6 MHz electromagnetic radiation. The majority ofwhole-body hyperthermia systems currently in clinical useemploy IR radiation to achieve systemic heating. Invasiveapproaches to systemic hyperthermia are extracorporealheating of blood, removed from the body via an arteriovenousshunt, prior to returning it to the circulation, as well asperitoneal irrigationwithheatedfluid (4).A useful schematicsummary of whole-body hyperthermia induction techniquesalong with references is provided by van der Zee (5).
All of these approaches involve a period of steadytemperature increase, followed by a plateau or equilibriumphase where the target temperature is maintained for any-where from 30 min to several hours, and finally a cool-downphase. Depending on the method of hyperthermia induction,the patient may be anesthetized, consciously sedated, admi-nistered analgesia, or not given any kind of medication atall. An epidural block is sometimes given to induce orincrease vasodilation. During radiant heat induction, thetemperature of the skin and superficial tissues (includingtumors) is higher than the core (rectal) temperaturewhereas during the plateau (maintenance) phase, theskin–superficial tissue temperature drops below the coretemperature. As already described, heat losses due to phy-siological mechanisms limit the rate of heating that can beachieved. When insulation of the patient with plastic foilwas added to hot air heating, the heating time to 41.8 8C wasdecreased from 230 to 150 min (65%), and further to 110 min(48%) by addition of a warm water perfused mattress (5).The homogeneity of the temperature distribution was alsosignificantly increased by the addition of insulation and thewater mattress. Noninvasive systemic hyperthermia meth-odologies typically produce heating rates of 1–10 8Ch�1
with 2–3 8Ch�1 being most common. More rapid heatingcan be achieved by the invasive techniques, at the expense ofgreater risk of infection and morbidity.
COMMERCIALLY AVAILABLE WHOLE-BODYHYPERTHERMIA SYSTEMS
A number of commercially available devices have resultedfrom the development of these initially experimental
HYPERTHERMIA, SYSTEMIC 45
systems. The Siemens–Pomp system has already been men-tioned, but is no longer commercially available. Similarly,neither the radiant heat chamber developed by Robins (3),and marketed as the Aquatherm system, nor the similarEnthermics Medical Systems RHS-7500 radiant heatdevice, both producing far IR radiation (IR C) in a moistair chamber, are currently being sold, though they arestill in use in several centers. A close relative is theIratherm2000 radiant heat chamber originally developedby von Ardenne and co-workers (6). In this device, water-filtered infrared radiators at 2400 8C emit their energy fromabove and below the patient bed, producing near-IR (IR A)radiation that penetrates deeper into tissue than far IRradiation, causing direct heating of the subcutaneous capil-lary bed. Thermal isolation is ensured by reflective foilsplaced around the patient. However, note that significantevaporative heat loss through perspiration can be a problemwith this system. Also with a significant market share is theHeckel HT 2000 radiant heat device in which patients lie ona bed enclosed within a soft-sided rectangular tent whoseinner walls are coated with reflective aluminum foil thatensures that the short wavelength infrared A and B radia-tion emitted by four radiators within the chamber uniformlybathes the body surface. Once the target temperature isreached, the chamber walls are collapsed to wrap around thebody, thereby preventing radiative and evaporative heatloss, and permitting maintenance of the elevated tempera-ture, as shown in Fig. 2.
Another radiant heat device, used mainly in Germany,is the HOT-OncoTherm WBH-2000 whole-body hyperther-mia unit which is a chamber that encloses all but thepatient’s head. Special light-emitting diode (LED) radia-tors deliver computer-generated, alloy-filtered IR A wave-lengths that penetrate the skin to deliver heat to thecapillary bed. The manufacturer claims that these wave-lengths also preferentially stimulate the immune system.Recently, Energy Technology, Inc. of China has releasedthe ET-SPACE whole-body hyperthermia system, which
produces IR A radiation in a small patient chamber intowhich warm liquid is infused to help increase the airhumidity and thereby reduce perspiration losses. A num-ber of low cost, far infrared, or dry, saunas are being soldto private clinics, health clubs, and even individuals fortreatment of arthritis, fibromyalgia, detoxification, andweight loss. Examples are the Smarty HyperthermicChamber, the TheraSauna, the Physiotherm, and theBiotherm Sauna Dome. Table 2 summarizes features ofthese commercially available whole-body hyperthermiadevices.
BIOLOGICAL EFFECTS OF SYSTEMIC HYPERTHERMIA
An understanding of the biological effects of systemichyperthermia is critical to both its successful inductionand to its therapeutic efficacy. Systemic responses to bodyheating, if not counteracted, undermine efforts to raisebody temperature, while cellular effects underlie boththe rationale for the use of hyperthermia to treat specificdiseases, and the toxicities resulting from treatment.Although improved technology has allowed easier andmore effective induction of systemic hyperthermia, mostof the recent clinical advances are due to better under-standing and exploitation of specific biological phenomena.
Physiological Effects of Elevated Body Temperature
The sympathetic nervous system attempts to keep all partsof the body at a constant temperature, tightly controlled bya central temperature ‘set point’ in the preoptic–anteriorhypothalamus and a variety of feedback mechanisms. Thethermostat has a circadian rhythm and is occasionallyreset, for example, during fever induced by infectiousagents and endotoxins, but not in endogenously inducedhyperthermia. Occasionally, it breaks down completely asin malignant hyperthermia or some neurological disordersaffecting the hypothalamus. Ordinarily, when core bodytemperature rises, the blood vessels initially dilate, heartrate rises, and blood flow increases in an effort to transportheat to the body surface where it is lost by radiation,conduction, and convection. Heart rate increases on averageby 11.7 beatsmin�1 8C�1 and typically remains elevated forseveral hours after normal body temperature is regained.Systolic blood pressure increases to drive the blood flow, butdiastolic pressure decreases due to the decreased resistanceof dilated vessels, thus there is an increase in cardiacoutput. Heart rate and blood pressure must therefore bemonitored during systemic hyperthermia, and whole-bodyhyperthermia is contraindicated in most patients withcardiac conditions. Interestingly, hyperthermia increasescardiac tolerance to ischemia/reperfusion injury probablydue to activation of manganese superoxide dismutase(Mn-SOD) and involvement of cytokines.
Respiration rate also increases and breathing becomesshallower. Perspiration results in evaporation of sweatfrom the skin and consequent cooling, while the respirationrate increases in order to increase cooling by evaporation ofmoisture from expired air. Weight loss occurs despite fluidintake. There is a decrease in urinary output and the urinehas a high specific gravity, concentrating urates and
46 HYPERTHERMIA, SYSTEMIC
Figure 2. Heckel HT-2000 radiant heat whole body hyperthermiasystem. Unit at the University of Texas Medical School at Houston.Patient is in the heat maintenance phase of treatment, wrapped inthe thermal blankets which form the sides of the chamber duringactive heating.
Ta
ble
2.
Co
mm
erc
iall
yA
va
ila
ble
Cli
nic
al
Wh
ole
-Bo
dy
Hy
perth
erm
iaD
ev
ices
Man
ufa
ctu
rer
Web
site
Dev
ice
Nam
eH
eati
ng
Mec
han
ism
Tem
per
atu
reR
an
ge,
8CA
pp
lica
tion
En
ergy
Tec
hn
olog
yh
ttp
://w
ww
.eti
.com
.cn
/EN
/pro
/pro
du
ct2.h
tmE
T-S
PA
CE
Mu
ltip
leIR
rad
iato
rs(I
RA
)39–41.8
On
colo
gy
Hec
kel
Med
izin
tech
nik
Gm
bH
htt
p://w
ww
.hec
kel
-med
izin
tech
nik
.de/
fram
eset
_e.h
tml
HT
2000
M4
300W
IRra
dia
tors
(IR
A,
B)
38.5
–40.5
On
colo
gy,
rheu
mato
logy
Hot
-On
coth
erm
htt
p://w
ww
.hot
-on
coth
erm
.com
/on
coth
erm
ia.h
tmW
BH
-2000
Mu
ltip
leL
ED
rad
iato
rs(I
RA
)37–42
On
colo
gy
Von
Ard
enn
eIn
stit
ut
fur
An
gew
an
dte
Med
izin
isch
eF
orsc
hu
ng,
Gm
bH
htt
p:/
/ww
w.a
rden
ne.
de/
med
_en
g/
Irath
erm
800
4IR
rad
iato
rs(I
RA
)37–38
Ph
ysi
cal
med
icin
e,co
mp
lem
enta
rym
edic
ine,
onco
logy
Irath
erm
1000
6IR
rad
iato
rs(I
RA
)37–39
Irath
erm
2000
10
IRra
dia
tors
(IR
A)
37–42
47
phosphates. In endogenously induced hyperthermia, butnot in fever, glomerular filtration, as evidenced by thecreatinine clearance, decreases with increasing tempera-ture. As already mentioned, metabolic rate increases non-linearly with temperature, which leads to an increase inblood sugar, decreased serum potassium levels, andincreased lactic acid production. All the above normalphysiological effects may be enhanced or counteracted byanesthesia or sedation, as well as by disease states such ascancer because of drugs used in treatment or intrinsicpathophysiological consequences of the disease.
At �42.5 8C, the normal thermocompensatory mechan-isms break down and the body displays the symptoms ofadvanced heat stroke, namely, lack of sweating, rapidheart beat, Cheyne–Stokes breathing, central nervoussystem disfunction, and loss of consciousness. Ultimately,breathing ceases despite the continuation of a heart beat.
Cellular Thermal Damage
When temperature is increased by a few degrees Celcious,there is increased efficiency of enzyme reactions (Arrhe-nius equation), leading to increased metabolic rates, but attemperatures > 40 8C molecular conformation changesoccur that lead to destabilization of macromolecules andmultimolecular structures, for example, to the side chainsof amino acids in proteins, which in turn inhibit enzymeaction. Small heat shock proteins (HSP) interact with theunfolding proteins to stabilize them and prevent theiraggregation and precipitation. Eventually, however, at�42 8C, complete denaturation of proteins begins thattotally disrupts many molecular processes, including deox-yribonucleic acid (DNA) repair. Thus systemic hyperther-mia can have significant effects when paired with drugsthat cause DNA damage (e.g., for chemotherapy of cancer).
Membranes are known to be extremely sensitive toheat stress because of their complex molecular composi-tion of lipids and proteins. At a certain temperature, lipidschange from the tightly packed gel phase to the lesstightly packed liquid crystalline phase, and permeabilityof the cell membrane (membrane fluidity) increases. Astemperature increases further, the conformation of proteinsalso becomes affected, eventually resulting in disorderlyrearrangement of the lipid bilayer structure and receptorinactivation or loss. Temperature changes of �5 8C arenecessary to cause measurable changes in normal cellmembrane permeability. Heat-induced cell membrane per-meability can be exploited to increase drug delivery, forexample, transdermally, or into tumor cells. Increased vas-cular permeability due to thermal increase of endothelialgap size also aids drug delivery into tumors. At highertemperatures, heat damage to membranes can cause celldeath, but it will also interfere with therapeutic approachesthat depend on membrane integrity (e.g., receptor targeteddrug delivery, antibodies, etc.). Irreversible disruption ofcytoplasmic microtubule organization and eventual disag-gregation, as well as disruption of actin stress fibers andvimentin filaments, occur at high temperatures (43–45 8C)above those used in whole-body hyperthermia, but thesecytoskeletal effects are of concern with loco-regional hyper-thermia.
A variety of effects in the cell nucleus also occur at hightemperatures (>41 8C) including damage to the nuclearmembrane, increases in nuclear protein content, changesin the structure of nucleoli, inhibition of DNA synthesisand chromosomal damage in S-phase. These changes innuclear structure compromise nuclear function and maycause cell death, though they are unlikely to be significantat the temperatures achieved in systemic hyperthermia.Disaggregation of the spindle apparatus of mitotic cellsmay be responsible for the high thermal sensitivity of cellsin mitosis, as well as in S phase. Hyperthermic inactivationof polymerase b, an enzyme primarily involved in DNArepair, is sensitized by anesthetics and may have a role toplay in the enhancement of the effects of ionizing radiationby systemic hyperthermia, as well as in augmenting thecytotoxic effect of drugs that cause DNA damage.
Metabolic Effects
Moderate increases in temperature lead to increased cel-lular reaction rates, which may be seen as increased oxy-gen consumption and glucose turnover. In consequence,cells may become deprived of nutrients, the intracellularATP concentration falls, accumulation of acid metabolitesincreases pH, and thermal sensitivity increases. Suchconditions are found in tumors and may contribute to theirsensitivity to heat. Further acidifying tumor cells duringhyperthermic treatment seems a promising approach as isdiscussed further below. At high temperatures, the citricacid cycle may be damaged leading to other acidic meta-bolites. Increased plasma acetate has been measured fol-lowing clinical whole-body hyperthermia treatments,which reduces both release of fatty acids from adiposetissue into plasma and subsequent lipid oxidation.
Endocrine Function
Increases in plasma levels of an array of hormones havebeen noted after whole-body hyperthermia. IncreasedACTH levels appear to be accompanied by increased levelsof circulating endorphins. This may explain the sense ofwell-being felt by many patients after systemic hyperther-mia treatment, and the palliative effect of hyperthermiatreatments for cancer. Increased secretion of somatotropichormone after systemic hyperthermia has also been mea-sured (7).
Thermal Tolerance
Thermal tolerance is a temporary state of thermal resis-tance, common to virtually all mammalian cells, whichdevelops after a prolonged exposure to moderate tempera-tures (40–42 8C), or a brief heat shock followed by incuba-tion at 37 8C, and also certain chemicals. The decay ofthermotolerance occurs exponentially and depends on thetreatment time, the temperature, and the proliferativestatus of the cells. Several days are usually required forbaseline levels of heat sensitivity to be regained, which hasimportant implications for fractionated therapy. When pHis lowered, less thermal tolerance develops, and its decay isslower. Thus the long periods at moderate temperatureachieved by clinical systemic hyperthermia systems should
48 HYPERTHERMIA, SYSTEMIC
induce thermal resistance in normal cells, while the acidicparts of tumors should be relatively unaffected. This hasnot, however, been studied clinically. The mechanismsinvolved in the induction of thermotolerance are not wellunderstood, but there is mounting evidence that heat shockproteins are involved.
Step-Down Sensitization
Another distinct phenomenon is step-down sensitization inwhich an exposure of cells to temperatures >43 8C resultsin increased sensitivity to subsequent temperatures of42 8C or lower. This can be important clinically for localand regional hyperthermia if there are marked variationsin temperature during the course of treatment, the mag-nitude of the effect depending on the magnitude of thetemperature change. It has been suggested that this phe-nomenon could be exploited clinically by administering ashort, high temperature treatment prior to a prolongedtreatment at a lower temperature, thereby reducing painand discomfort. Since temperatures >43 8C cannot be tol-erated systemically, a local heat boost would be required totakeadvantageof this effect for whole bodyhyperthermia. Sofar, there is no evidence that tumor cells are differentlysensitized by step-down heating than normal cells.
Effect of Hyperthermia on Tumors
It was initially thought that tumor cells have intrinsicallyhigher heat sensitivity than normal cells, but this is notuniversally true. Although some neoplastic cells are moresensitive to heat than their normal counterparts, thisappears to be the case at temperatures higher than thoseused in systemic hyperthermia. Tumors in vivo, on theother hand, often do have a higher thermal sensitivity thannormal tissues because of abnormal vasculature (reducedblood flow), anaerobic metabolism (acidosis), and nutrientdepletion. Due to their tortuous and poorly constructedvasculature, tumors have poor perfusion, thus heat dis-sipation by convection is reduced. At high temperatures(43 8C and up) this means that tumors become a heatreservoir with a consequent rise in temperature, whichif maintained for too long damages the microcirculationand further impairs convective heat loss. Also increasedfibrinogen deposition at damaged sites in the vascular wallleads to clusion of tumor microvessels. Significant heatingof the tumor cells results, which may be directly cytotoxic.Additionally, the impaired blood flow brings about acidosis,increased hypoxia and energy depletion all of whichincrease the heat sensitivity of tumor cells (8). At lowertemperatures, typical of those achieved in whole-bodyhyperthermia, blood flow increases (9) though the mechan-ism is not well understood. For these reasons, along withthe historical evidence for antitumor effects of fever and themetastatic nature of malignant disease, cancer has becomethe main focus of systemic hyperthermia.
Systemic hyperthermia results in increased delivery ofdrugs to tumor sites because of increased systemic bloodflow. It can also increase blood vessel permeability byincreasing the effective pore size between the loosely boundendothelial cells forming tumor microvessels, permittinglarger molecules, such as nanoparticles and gene therapyvectors, to pass into the interstitium (10). Figure 3 showsincreased uptake of 210 nm liposomes in rat breast tumorsafter 1 h of 41.5 8C whole-body hyperthermia. Heat mayalso be toxic to endothelial cells, resulting in a transientnormalization of vascular architecture and improvementin blood flow (11). Another barrier to drug delivery is thehigh interstitial pressure of many tumors. Since whole-body hyperthermia, even at fever-range temperatures,causes cell death (apoptosis and necrosis) within tumorsit reduces the oncotic pressure allowing greater penetrationof large molecules. Table 3 summarizes the interactions ofsystemic hyperthermia which facilitate nanoparticle deliv-ery to tumors.
HYPERTHERMIA, SYSTEMIC 49
0.0
1.0
2.0
100 nm 210 nm
41.5
˚C/3
7˚C
up
take
rat
io
Liposome size
Figure 3. Increase in tumor uptake of large liposomes after 1 hof 41.5 8C whole-body hyperthermia. Systemic heat treatmentincreased the effective pore size from �210 to 240 nm. Becauseof the large pore size in MTLn3 tumors, 100 nm (average diameter)liposomes were able to pass into the tumor equally well at normaland elevated temperatures. The increased effective pore size dueto hyperthermia allowed larger 200 nm liposomes, which werepartially blocked at normal temperatures, to pass more effectivelyinto the tumor.
Table 3. Whole-Body Hyperthermia Facilitates Nanoparticle Therapy
Heat Interaction Therapeutic Effect
" Blood flow " Nanoparticle delivery to tumor" In endothelial gap size " Nanoparticles in interstitium" Endothelial cell apoptosis/necrosis ! transient normalization of vasculature " Nanoparticles in interstitium" Tumor cell apoptosis/necrosis # oncotic pressure " Nanoparticles in interstitiumTemperature-dependent " in permeability of liposome bilayer " And synchronization of drug releaseCellular and molecular effects in tumor " Drug in tumor cell " drug efficacyDirect interactions with drug " Drug efficacy
Whole-Body Hyperthermia and the Immune System
An increase in ambient temperature can serve as a naturaltrigger to the immune system and it appears that the thermalmicroenvironment plays a critical role in regulating events inthe immune response. The early work of Coley on cancertherapy with infectious pyrogens implicated fever-inducedimmune stimulation as the mediator of tumor responses (1).While there have been numerous in vitro studies of the effectof temperature on components of the immune system, indi-cating that the thermal milieu regulates T lymphocytes,natural killer (NK) cells, and dendritic cells (DC), in vivoexaminations of the immune effects of systemic hyperther-mia are relatively few. Initial animal model studies con-cluded that whole-body hyperthermia resulted inimmunosuppression, but high temperatures were used,tumors were mostly immunogenic, and immune responsewas merely inferred from the incidence of metastatic spreadrather than from measurement of specific markers ofimmune system activation. The majority of in vivo studiesin animals provide evidence of a nonspecific host reactionin response to hyperthermia in which both T and Blymphocytes, as well as macrophages, are involved (12).Although NK cells are intrinsically more sensitive in vitroto heat than B and T cells, their activation by systemichyperthermia has been observed. Microwave inducedwhole-body hyperthermia of unrestrained, unanesthe-tized mice at 39.5–40 8C for 30 min, three or six timesweekly, resulted in increased NK cell activity and reducedpulmonary metastasis in tumor-bearing mice, but none innormal mice (13). Evidence for hyperthermia-inducedhuman tumor lysis by IL-2 stimulated NK cells activatedby HSP72 expression also exists (14). Increased numbersof lymphocyte-like cells, macrophages, and granulocytesare observed in the tumor vasculature and in the tumorstroma of xenografts and syngeneic tumors in mice imme-diately following a mild hyperthermia exposure for 6–8 h.In the SCID mouse/human tumor system tumor cellapoptosis seen following treatment was due largely tothe activity of NK cells. The investigators hypothesizeheat dilatation of blood vessels and increased vessel per-meability may also give immune effector cells greateraccess to the interior of tumors (15). In balb/C mice,fever-range whole-body hyperthermia increased lympho-cyte trafficking, resulting in early responsiveness to anti-gen challenge (16). Thus systemic hyperthermia may bean effective, nontoxic adjuvant to immunotherapy.
A recent clinical study examined the effect of whole-body hyperthermia combined with chemotherapy on theexpression up to 48 h later of a broad range of activationmarkers on peripheral blood lymphocytes, as well as serumcytokines and intracellular cytokine levels in T cells, andthe capacity of these cells to proliferate. Immediately aftertreatment with 60 min of 41.8 8C WBH as an adjunct tochemotherapy, a drastic but transient, increase in periph-eral NK cells and CD56þ cytotoxic T lymphocytes wasobserved in the patients’ peripheral blood. The numberof T cells then briefly dropped below baseline levels, aphenomeonon that has also been observed by others (17).A marked, but short-lived, increase in the patients’ serumlevels of interleukin-6 (IL-6) was also noted. Significantly
increased serum levels of tumor necrosis factor-alpha(TNF-alpha) were found at 0, 3, 5 and 24 h posttreatment.Further immunological consequences of the treatmentconsisted of an increase in the percentage of peripheralcytotoxic T lymphocytes expressing CD56, reaching a max-imum at 48 h post-WBH. Furthermore, the percentage ofCD4+ T cells expressing the T cell activation marker CD69increased nearly twofold over time, reaching its maximumat 48 h. Since similar changes were not observed inpatients receiving chemotherapy alone, this study pro-vided strong evidence for prolonged activation of humanT cells induced by whole-body hyperthermia combined withchemotherapy (18).
Activation of monocytes has been observed following hotwater bath immersion such that response to endotoxinstimulation is enhanced with concomitant release ofTNF-a. Macrophage activation and subsequent lysosomalexocytosis were observed in the case of a patient treated forliver metastases by hyperthermia. Lysosomal exocytosisinduced by heat may be an important basic reaction of thebody against bacteria, viruses, and tumor growth and wasproposed as a new mechanism of thermally induced tumorcell death mediated by an immune reaction (19).
Several investigators have suggested that the immunechanges seen during in vivo whole-body hyperthermia aremediated by elevations in the plasma concentrations ofeither catecholamines, growth hormone, or beta-endorphins.In volunteers immersed in a heated water bath, neitherrecruitment of NK cells to the blood, nor the percentagesor concentrations of any other subpopulations of blood mono-nuclear cells were altered by hormone blockade. However,somatostatin partly abolished the hyperthermia inducedincrease in neutrophil number. Based on these data andprevious results showing that growth hormone infusionincreases the concentration of neutrophils in the blood, itwas suggested that growth hormone is at least partlyresponsible for hyperthermia induced neutrophil increase.A similar study suggested that hyperthermic inductionof T lymphocytes and NK cells is due to increased secre-tion of somatotropic hormone (7).
The peripheral blood level of prostaglandin E2 (PGE2),which may act as an angiogenic switch, transforming alocalized tumor into an invasive one by stimulating newblood vessel growth, and which also has an immunosup-pressive effect, is elevated in patients with tumors com-pared to healthy control subjects. In a clinical study ofcancer patients receiving 1–2 h of 41.8–42.5 8C whole-bodyhyperthermia, or extracorporeal hyperthermia, bloodlevels of PGE2 decreased markedly after treatment andcorrelated with tumor response (20).
In addition to their role as protectors of unfoldingproteins, extracellular heat shock proteins (HSP) can actsimultaneously as a source of antigen due to their ability tochaperone peptides and as a maturation signal for dendri-tic cells, thereby inducing dendritic cells to cross-presentantigens to CD8þ T cells (21). Heat shock proteins can alsoact independently from associated peptides, stimulatingthe innate immune system by eliciting potent proinflam-matory responses in innate immune cells. The heat shockresponse also inhibits cyclooxygenase-2 gene expression atthe transcriptional level by preventing the activation of
50 HYPERTHERMIA, SYSTEMIC
nuclear factor-kappaB (NFkB) (22). Thermal upregulationof HSPs (HSP70 and HSP110) is strongest in lymphoidtissues and may relate to the enhanced immune responsesthat are observed during febrile temperatures. It has beenproposed that local necrosis induced by hyperthermictreatment induces the release of HSPs, followed by uptake,processing and presentation of associated peptides by den-dritic cells. By acting as chaperones and as a signal fordendritic cell maturation, HSP70 might efficiently primecirculating T cells. Therefore, upregulating HSP70 andcausing local necrosis in tumor tissue by hyperthermiaoffers great potential as a new approach to directly activatethe immune system, as well as to enhance other immu-notherapies (23,24).
CLINICAL TOXICITIES OF WHOLE-BODY HYPERTHERMIATREATMENT
At fever-range temperatures, adverse effects of systemichyperthermia treatment are minimal however, at highertemperatures they can be significant, even fatal. On theother hand, the teratogenic effects (birth defects, stillbirths, spontaneous abortions) and 8Cular damage (catar-act induction) resulting from electromagnetic fields used inlocal hyperthermia are not seen in systemic hyperthermia.The transient cardiorespiratory effects of elevated tem-perature can, however, lead to severe toxicity. Elevatedheart rate, especially at high temperatures may result inarrythmias or ischemic heart failure, consequentlypatients have to be very carefully screened with regardto their cardiac status. Beta blockade has generally beenfound to be deleterious although infusion of esmolol hasbeen safely carried out (25). Pulmonary hypertension andedema due to capillary leak may also be seen, but like thecardiac effects, these return to baseline a few hours aftertreatment. Increased serum hepatic enzymes have beennoted, but these may be cancer related. All these toxicitiesare less prevalent or less severe with radiant heat systems,particularly at lower temperatures, and when light con-scious sedation is used rather than general anesthesia. Forexample, decreased platelet count, decreased plasma fibri-nogen, and other factors leading to increased blood clottinghave been noted, particularly in extra-corporeal hyper-thermia, but also with other methods of heating carriedout under inhalation-administered anesthesia drugs.On the other hand, with whole-body hyperthermia underconscious sedation there is no evidence of plateletdrops (26) and animal studies even show platelet stimula-tion providing protection against radiation inducedthrombocytopenia.
Since systemic hyperthermia is almost never used as asingle treatment modality, it is important to recognize thatwhole-body hyperthermia combined with radiation andchemotherapy can enhance some of the toxicities asso-ciated with these modalities. For example, the cardiotoxi-city of doxorubicin and both the renal toxicity andhematological toxicity of platinum agents may increaseunder hyperthermia (27), while the muscle and peripheralnervous system effects of radiation and some drugs can alsobe enhanced (28). Bone marrow suppression is the limiting
toxicity of many chemotherapy drugs but there is little datato suggest that whole body hyperthermia exacerbates thiseffect. On the contrary, the synergy of hyperthermia withseveral chemotherapy agents may mean that lower dosescan be used, resulting in less toxicity. For example, sys-temic hyperthermia combined with carboplatin achievestherapeutic results without elevation of myelosuppressionand responses have occurred at lower than normal doses(29). Pressure sores can easily develop at elevatedtemperatures thus care must be taken not only in patientplacement and support, but also with application of mon-itoring devices. If heat dissipation is locally impaired, forexample, at pressure points, hot spots occur that can lead toburns. This is rarely a problem with fever-range whole-body hyperthermia, but in anesthetized patients under-going high heat regimens burns are not uncommon.
Following systemic hyperthermia treatments, malaiseand lethargy are almost universally experienced althoughthese may be counteracted by pain relief and a sense ofwell-being due to released endorphins. However, the fasterthe target temperature is reached, the less the exhaustion(6), thus attention to minimizing heat dissipation duringthe heat-up phase and using efficient heating devices, suchas those that generate heat by several mechanisms (e.g.,radiant heat and EM fields), add a regional heat boost, orproduce near-IR radiation that is preferentially absorbed,is advantageous to patient well being. Fever after treat-ment in the absence of infectious disease is not uncommonand may be associated with an inflammatory response totumor regression. Nausea and vomiting during the firstcouple of days after treatment are also common. Outbreaksof herpes simplex (cold sores) in susceptible individualshave also been noted, but are easily resolved with acyclovir.
THERMAL DOSE
The definition of dose for systemic hyperthermia is proble-matic. An applied dose would be the amount of heat energygenerated or delivered to the body but even if it can bemeasured, this quantity does not predict biological effects.By analogy with ionizing radiation, the absorbed dosewould be amount of thermal energy absorbed per unitmass of tissue (Jkg�1), however, this is not a quantitythat can be readily measured, or controlled, neither wouldit necessarily predict biological effects. As indicated in theprevious sections, the effects of systemic hyperthermiadepend on (1) the temperature, and (2) the duration ofheating, but not on the energy required to produce thetemperature rise. This leads to the concept of time at agiven temperature as a practical measure of dose. Inreality, however, temperature is seldom constant through-out a treatment, even in the plateau phase of systemichyperthermia, so time at temperature is at best a crudemeasure. Nonetheless, it is the one that is used most oftenclinically for whole-body hyperthermia because of its sim-plicity. Ideally, the dose parameter should allow for com-parison of treatments at different temperatures. Based onthe Arrhenius relationship and measured cell growth inhi-bition curves, the heating time at a given temperaturerelative to the heating time at a standard temperature or
HYPERTHERMIA, SYSTEMIC 51
thermal dose equivalent (TDE), was defined empirically as,
T1 ¼ t2 RðT1�T2Þ ð10Þ
A discontinuity occurs in the temperature-time curvesbetween 42 and 43 8C for both cells in culture and heatedtissues, thus the value of R changes for temperatures abovethe transition: R � 2< 42.5 8C and R � 5> 42.5 8C in vitrowhile for in vivo heating studies, R ¼ 2.1 below the transi-tion temperature and 6.4 above 42.5 8C. In practice, a finitetime is required for the body or tissue of interest to reach thetarget temperature, temperature fluctuates even after thetarget temperature is reached, and there is a cooling periodafter heating ceases. If the temperature is measured fre-quently throughout treatment, the temperature–timecurves can be integrated to provide the accumulated ther-mal dose that produces an equivalent effect to that resultingfrom holding the cells–tissue at a constant reference tem-perature for a given a period of time:
t43 ¼Zt f
ti
R43�TðtÞdt ð11Þ
where ti and tf are the initial and final times of the heatingprocedure (30). This thermal isoeffect dose (TID) is usuallyexpressed in minutes is sometimes known as the tdm43 orthe cumulative equivalent minutes (CEM 43 8C). While abiological factor has now been built in to the dose measure,and the integrated TID allows for temperature variationsduring heat-up and cool-down phases, it does not take intoaccount thermal tolerance and step-down sensitization. Noris it particularly relevant to clinical whole-body hyperther-mia where multiple physical and biological effects combinein a complex manner although for a given patient, time–temperature profiles are generally reproducible from onetreatment to another. A further modification attempts totake into account temperature inhomogeneity through themeasurement of temperature at multiple sites and definingT90, namely, that temperature exceeded by 90% of themeasurements (or correspondingly 20%: T20; or 50%:T50). The TID is then expressed as cumulative equivalentminutes that T90 is equal to 43 8C (CEM 43 8C T90) (31).
The efficiency of adjuvant hyperthermia in enhancingthe biological effectiveness of other treatments is oftenreported in terms of the thermal enhancement factor(TEF) or thermal enhancement ratio (TER). This quantityis defined in terms of the isoeffect dose as,
TER ¼
dose of treatment to achieve
a given endpoint
dose of treatment with heat
to achieve the same endpoint
ð12Þ
In clinical and laboratory studies, the TER is oftencomputed on the basis of isodose rather than isoeffect,for example, in the case of hyperthermia plus druginduced arrest of tumor growth, TER ¼ TGDHT/TGTRT,where TGDHT is the tumor growth delay due tohyperthermia plus chemotherapy, and TGTRT is thetumor growth delay resulting from chemotherapy at roomtemperature. Similarly, the enhancing effect of hyperther-
mia on radiation treatment may be expressed throughTER ¼ D0HT/D0RT or TER ¼ LD50HT/LD50RT, where D0is the time required to reduce survival to 1/e of its initialvalue, and LD50 is the lethal dose to 50% of cells.
TEMPERATURE MEASUREMENT
Since systemic hyperthermia achieves a uniform tempera-ture distribution, except for possible partial sanctuary sites,thermometry for systemic hyperthermia is much less chal-lenging than for regional or intracavitary hyperthermia, butit is still important to prevent adverse effects, especiallyburns. Also, convection can induce steep thermal gradients,especially around major blood vessels, so that careful place-ment of temperature probes is required. Most practitionersof whole-body hyperthermia measure temperature in sev-eral locations, typically the rectum, the esophagus, and atseveral skin sites. During heat-up, the esophageal tempera-ture is usually 1–2 8C higher than the rectal temperature,but during plateau phase it drops to 0.5–1.5 8C below therectal temperature. Continuous and accurate temperaturemeasurement is particularly important when temperatures>418C are to be achieved, as critical, life-threateningchanges can occur in minutes or even seconds and overchanges in temperature of as little as 0.1–0.2 8C because ofthe nonlinear response to temperature. For moderate tem-perature systemic hyperthermia, temperature measure-ment to within 0.1 8C is usually adequate, but a precisionof 0.01 8C is desirable when heating to >41 8C and alsoallows determination of the specific absorption rate from theslope of the temperature versus time curve. The tempera-ture measuring device must be insensitive to all otherinfluences, such as ambient temperature, moisture, nearbyelectromagnetic fields, and so on and satisfying this criter-ion can be difficult. Frequent calibration of thermometers inthe working range of temperatures is important since somethermometers appear fine at 30 8C, but drift substantially at40 8C and above. Stringent quality control of any thermo-metry system is required to monitor accuracy, precision,stability, and response time.
Table 4 summarizes the different types of thermometerprobes available for internal and external body tempera-ture measurements, and their relative merits and disad-vantages for systemic hyperthermia. Thermistors are mostoften used for standard temperature monitoring sites whilethermocouples are used for tumor or other intra-tissuemeasurements. Recently, noninvasive methods of tem-perature measurement have been developed that arebeginning to see application in hyperthermia. Thermogra-phy provides a two-dimensional (2D) map of surface tem-perature by measurement of infrared emission from thebody, though deep-seated hot structures may be visualizedbecause of heat carried by blood flow from the interior heatsource to the skin. It is useful to detect skin hotspots andtherefore in burn prevention. Since temperature-inducedchanges in the mechanical properties of tissue lead toaltered ultrasound propagation velocity, mapping of ultra-sound velocity can also provide a visual map of tempera-ture. Tomographic reconstruction of 2D or 3D temperatureis theoretically possible, but it is difficult in practicebecause of the heterogeneity of tissue characteristics. A
52 HYPERTHERMIA, SYSTEMIC
Ta
ble
4.
Tem
pera
tures
Pro
bes
for
Sy
stem
icH
yp
erth
erm
ia
Pro
be
Typ
eM
easu
rem
ent
Pri
nci
ple
Acc
ura
cyS
ensi
tivit
yS
tabil
ity
Ad
van
tages
orD
isad
van
tages
Cli
nic
al
Exp
an
sion
ofm
ercu
ryor
alc
ohol
ingla
ssM
oder
ate
�0.1
8CL
owH
igh
Larg
esi
ze,
infl
exib
le.
Slo
wre
spon
se.
Pla
tin
um
resi
stan
ceth
erm
omet
erL
inea
rre
sist
an
cech
an
ge
wit
hte
mp
eratu
reH
igh�
0.0
28C
Use
das
stan
dard
for
cali
bra
tion
ofot
her
typ
esof
ther
mom
eter
s.
Exp
ensi
ve.
Dif
ficu
ltto
cali
bra
te.
Larg
esi
ze.
Sen
siti
ve
tosh
ock
.
Th
erm
ocou
ple
See
bec
kef
fect
:te
mp
eratu
red
epen
den
tvol
tage
dif
fere
nce
bet
wee
ntw
oco
nd
uct
ors
mad
eof
dif
fere
nt
met
als
Mod
erate
�0.1
8CM
oder
ate
toh
igh
Mod
erate
Sm
all
sen
sor.
Non
lin
ear
vol
tage
chan
ge
wit
hte
mp
.S
ensi
tive
toE
Mfi
eld
s.C
an
’th
an
dle
stee
pte
mp
.gra
die
nts
.
Th
erm
isto
r(e
.g.,
Bow
man
Loo
pL
ars
enp
robe)
Inver
sere
lati
onsh
ipbet
wee
nte
mp
eratu
rean
dse
mic
ond
uct
orre
sist
an
ce
Hig
h<
0.0
58C
Hig
hP
oor
Req
uir
efr
equ
ent
reca
libra
tion
Sh
ort
tim
eco
nst
an
t.N
otin
terc
han
gea
ble
.S
ensi
tive
toE
Mfi
eld
s.
GaA
sT
emp
eratu
resp
ecifi
cabso
rpti
onM
oder
ate
Low
Sm
all
size
Op
tica
l(fi
ber
opti
cp
robe)
:C
han
ge
w/t
emp
.:N
otse
nsi
tive
toE
Mfi
eld
s.S
ma
llsi
ze.
LC
Dbir
efri
ngen
tcr
yst
al
flu
ores
cen
tp
hos
ph
orC
olor
refl
ecta
nce
Low
Low
Un
stable
Ref
ract
ion
ofp
olari
zed
ligh
tL
owD
ecay
offl
uor
esce
nce
Ver
yh
igh
53
Ta
ble
5.
Su
mm
ary
of
Cli
nic
al
Tria
lso
fW
ho
le-B
od
yH
yp
erth
erm
iaa
Fir
stA
uth
orP
ubli
cY
ear
Stu
dy
Typ
eN
um
ber
ofP
ati
ents
Dis
ease
Pro
toco
lR
esu
ltof
WB
HR
efer
ence
,P
MID
WB
HA
lon
eK
raybil
l,W
.G.
2002
Ph
ase
IA
dvan
ced
soli
dtu
mor
s3–6
hat
39.5
–40.0
8CW
ell
tole
rate
dN
osi
gn
ifica
nt
ad
ver
seev
ents
#in
circ
ula
tin
gly
mp
hoc
yte
s
16,
12028640
Ste
inh
au
sen
,D
.1994
Ph
ase
I103
Ad
van
ced
refr
act
ory
orre
curr
ent
can
cers
1h
at
41.8
8Cþ
hyp
ergly
cem
iaþ
hyp
erox
emia
Min
imal
sid
eef
fect
s52
resp
onse
s(5
0%
)8023241
WB
Hþ
Ch
emoth
era
py
Bak
shan
deh
,A
.2003
Ph
ase
II25
Non
met
ast
ati
cm
ali
gn
an
tp
leu
ral
mes
oth
elio
ma
1h
at
41.8
8Cþ
ifos
fam
ide
þca
rbop
lati
nþ
etop
osid
eG
rad
eII
I/IV
neu
trop
enia
an
dth
rom
boc
yto
pen
ia5
part
ial
rem
issi
ons
(20%
)
12609573
Bu
ll,
J.M
.1992
Ph
ase
II17
Ad
van
ced
met
ast
ati
csa
rcom
a2
hat
41.8
–42.0
8Cþ
BC
NU
Lim
itin
gto
xic
ity
¼th
rom
boc
yto
pen
ia7
resp
onse
s/S
D(4
1%
)"
surv
ival
33,
1607734
Bu
ll,
J.M
.2002
Ph
ase
I13
Vari
ous
chem
oth
erap
yre
sist
an
tca
nce
rs6
hat
40.0
8Cþ
dox
ilþ
5-F
Uþ
met
ron
omic
inte
rfer
on-a
Gra
de
III
toxic
itie
s9
resp
onse
s/S
D(6
9%
)
60
Bu
ll,
J.M
.2004
Ph
ase
I33
Ad
van
ced
met
ast
ati
cca
nce
rs(G
I,bre
ast
,h
ead
an
dn
eck
,sa
rcom
a,
neu
roen
doc
rin
e)
6h
at
40.0
8Cþ
cisp
lati
nþ
gem
cita
bin
eþ
inte
rfer
on-a
20
resp
onse
s/S
D(6
6%
)"
surv
ival"
qu
ali
tyof
life
35
Dou
wes
,F
.2004
Pil
ot21
Ovari
an
can
cer
1-2
hat
41.5
–42.0
8Cþ
cisp
lati
nor
carb
opla
tin
þh
yp
ergly
cem
ia
18
resp
onse
s/S
D(8
6%
)"
qu
ali
tyof
life
15108039
En
gel
hard
t,R
.1990
Pil
ot23
Ad
van
cem
etast
ati
cm
elan
oma
1h
at
41.0
8Cþ
cisp
lati
nþ
dox
oru
bic
inS
ligh
t"
inm
yel
otox
icit
y10
resp
onse
s/S
DR
esp
onse
rate
¼th
at
inli
tera
ture
for
chem
oalo
ne
52,
2198312
Gu
an
,J.
2005
Ph
ase
II32
Ad
van
ced
can
cers
94%
resp
onse
s/S
DP
ain
red
uct
ion
inall
pts
.In
crea
sed
KP
SD
ecre
ase
dtu
mor
mark
ers
65
Heg
ewis
ch-B
eck
er,
S.
2002
Ph
ase
II41
Pre
trea
ted
ad
van
ced
met
ast
ati
cco
lore
ctal
can
cer
1h
at
41.8
þox
ali
pla
tin
þle
uco
vor
inþ
5F
UN
oex
cess
toxic
ity
31
resp
onse
s/S
D(7
6%
)55,
12181242
Hil
deb
ran
dt,
B.
2004
Ph
ase
I/II
28
Met
ast
ati
cco
lore
ctal
can
cer
1h
at
41.8
–42.1
8Cþ
hyp
ergly
cem
iaþ
hyp
erox
emia
þfo
lin
icaci
dþ
5-F
Uþ
mit
omyci
nC
Gra
de
III/
IVto
xic
itie
s11
resp
onse
s/S
D(3
9%
)44,
15204528
54
Hou
,K
.2004
Ph
ase
II54
Ad
van
ced
can
cers
1–2
hat
41.8
–42.5
8C,
extr
aco
rpor
eal
þch
emot
her
ap
yvs.
chem
oth
erap
yalo
ne
75.3
%re
spon
ses/
SD
72.6
%#
tum
orm
ark
ers
70%
pain
reli
efim
pro
ved
slee
p"
wei
gh
t,ap
pet
ite,
KP
SA
llsi
gn
ifly>
con
trol
Rev
ersi
ble
toxic
itie
s
68
Ism
ael
-Zad
e,R
.S.
2005
Pil
ot5
Ped
iatr
icre
nal
cell
carc
inom
a3
hat
41.8
–42.5
8Cþ
dox
oru
bic
inþ
inte
rfer
on-a
No
com
pli
cati
ons
5re
spon
ses
(100%
)15700247
Ku
rpes
hev
,O
.K.
2005
Ph
ase
II42
Vari
ous
dis
sem
inate
dca
nce
rs1–2
hat
41.0
–42.3
8Cþ
pol
y-c
hem
oth
erap
yR
egre
ssio
nof
met
ast
ase
s.P
ain
red
uct
ion
66
Ric
hel
,O
.2004
Ph
ase
II21
Met
ast
ati
can
dre
curr
ent
cerv
ical
can
cer
1h
at
41.8
8Cþ
carb
opla
tin
Gra
de
III/
IVle
uco
pen
ia,
thro
mbop
enia
,an
emia
,re
nal
toxic
ity
16
resp
onse
s/S
D(7
6%
)
57,
15581981
Rob
ins,
H.I
.1993
Ph
ase
I30
Vari
ous
refr
act
ory
can
cers
1h
at
41.8
8Cþ
carb
opla
tin
Myel
otox
icit
y9
resp
onse
s(3
0%
)53,
8355046
Rob
ins,
H.I
.1997
Ph
ase
I16
Vari
ous
refr
act
ory
can
cers
1h
at
41.8
8Cþ
L-P
AM
Low
erp
late
let
nad
irm
yel
osu
pp
ress
ion
8re
spon
ses/
SD
(50%
)
48,
8996137
Str
obl,
B.
2004
Ph
ase
II7
Met
ast
ati
cce
rvic
al
can
cer
1h
at
41.5
–41.8
8Cþ
pacl
itaxel
þca
rbop
lati
nG
rad
eII
alo
pec
iaG
rad
eII
I/IV
thro
mbop
enia
,n
eutr
open
ia"
surv
ival
58
Wes
term
an
nA
.M.
2001
Ph
ase
II14
Pla
tin
um
resi
stan
tov
ari
an
can
cer
1h
at
41.8
8Cþ
carb
opla
tin
Gra
de
IVth
rom
boc
yto
pen
ia,
gra
de
III
neu
trop
enia
9re
spon
ses/
SD
(64%
)
11378341
Wes
term
an
nA
.M.
2003
Ph
ase
II95
Met
ast
ati
csa
rcom
a1
hat
41.8
8Cþ
ifos
fam
ide
þca
rbop
lati
nþ
etop
osid
eN
eutr
open
ia,
thro
mboc
yto
pen
ia,
infe
ctio
n58
resp
onse
s/S
D(6
1%
)50,
12759526
WB
Hþ
Ra
dia
tion
Over
gaard
,J.
1995
Ran
dom
ized
mu
ltic
ente
r70
Met
ast
ati
cm
elan
oma
1h
at
438C
þfr
act
ion
ate
dR
Tvs.
FR
Talo
ne
Imp
roved
loca
ltu
mor
con
trol
,"
surv
ival
41,
7776772
Rob
ins,
H.I
.1990
Pil
ot8
Nod
ula
rly
mp
hom
a,
chro
nic
lym
ph
ocyti
cle
uk
emia
41.8
8Cþ
TB
Ivs.
LO
Nþ
TB
I8
resp
onse
s/S
D"
surv
ival
24,
2182581
aP
ubli
shed
sin
ce1990.
55
number of magnetic resonance (MR) techniques have beenused for thermal mapping and BSD Medical and SIEMENSMedical Systems have collaborated to develop a hybridhyperthermia/MRI system, although it is not a whole-bodyhyperthermia machine. Currently, the most widelyaccepted MR technique is the proton resonance frequency(PRF) method that exploits the temperature dependence ofthe chemical shift of water. Unlike the value of the waterspin-lattice relaxation time or the molecular diffusioncoefficient, both of which have been used for MRI tempera-ture measurements, the thermal coefficient relating tem-perature to the water chemical shift has been shown to beessentially independent of tissue type and physiologicalchanges induced by temperature (32). Recently an inter-leaved gradient echo–echo planar imaging (iGE-EPI)method for rapid, multiplanar temperature imaging wasintroduced that provided increased temperature contrast-to-noise and lipid suppression without compromising spa-tio-temporal resolution (33).
CLINICAL EXPERIENCE
Cancer
Systemic hyperthermia has been used mostly for treatmentof cancer because of its potential to treat metastatic dis-ease. Initial treatments aimed to produce direct killing oftumor cells based on the premise, now understood not to beuniversally true, that cancer cells are more susceptible toelevated temperatures than normal cells, and the higherthe temperature the greater the tumor cell kill. Maximallytolerated temperatures of 41.5–42 8C were therefore main-tained for 1–2 h as the sole treatment. Response rates were,however, disappointing. Tumor regressions were observedin less than half the cases, no tumor cures were achieved,and remissions were of short duration. It became apparentthat the heterogeneity of cell populations within tumors,along with micro-environmental factors, such as blood/nutrient supply, pH, and oxygen tension prevent the ther-motoxic results achieved in the laboratory. Consequently,the focus of research on systemic hyperthermia shifted tousing hyperthermia as an adjunct to other cancer thera-pies, principally chemotherapy and radiotherapy. It isimportant to note that because of the experimental statusof systemic hyperthermia treatment for cancer, almost allclinical trials, summarized in Table 5, have been performedon patients with advanced disease for whom whole-bodyhyperthermia, either as a sole therapy, or as an adjunct, isa treatment of last resort. In these cases, any responsewhatsoever is often remarkable. Nonetheless, a number ofhyperthermia centers in Europe have discontinued sys-temic hyperthermia because the high temperature proto-cols required intensive patient care and led to unacceptabletoxicities, especially in light of the efficacy and reducedtoxicities of newer generation chemotherapies. Large, ran-domized, multicenter, Phase III trials are, however, neededto firmly establish the benefits of systemic hyperthermia inconjunction with chemotherapy and radiation. Also, vali-dation and optimization of fever-range temperature proto-cols are much needed.
Systemic Hyperthermia and Chemotherapy. The bene-ficial interaction of hyperthermia with several classes ofchemotherapy agents, acting via several mechanisms assummarized in Table 6, has spurred a variety of thermo-chemotherapy regimens and several clinical trials of sys-temic hyperthermia and chemotherapy are ongoing. Whilethe results have been mixed, elevated response rates wererecorded in the treatment of sarcoma when systemichyperthermia was combined with doxorubicin and cyclo-phosphamide (54) or BCNU (34). Systemic hyperthermia isthe only way to heat the lung uniformly, and impressiveresponse rates and increased durations of response havebeen achieved in both small cell and nonsmall cell lungcancer treated with the combination of whole bodyhyperthermia at 41 8C for 1 h with adriamycin, cyclopho-sphamide, and vincristine (ACO protocol) (34). Neuroendo-crine tumors also appear to have increased sensitivity tosystemic hyperthermia and multidrug chemotherapy (51).
Optimal combination of whole-body hyperthermia withchemotherapy requires an understanding of the mechan-isms of interaction of heat with individual drugs or drugs incombination. Preclinical data is consistent with the conceptthat the timing of chemotherapy during whole-bodyhyperthermia should affect therapeutic index. For exam-ple, Fig. 4 shows the effect on tumor cures in mammarycarcinoma bearing rats of 6 h of 40 8C whole-bodyhyperthermia administered with, or 24 or 48 h after gem-citabine. A synergistic response was obtained whenhyperthermia was begun with gemcitabine administrationor 48 h later. The effect of gemcitabine was completelynegated, however, when hyperthermia was administered24 h after the start of heating, perhaps due to cell cycleeffects. With cisplatin, the greatest therapeutic index isachieved if the drug is given 24 h before the start of whole-body hyperthermia, thereby preventing thermal augmen-tation of cisplatin induced nephrotoxicity (55). In a clinicalinvestigation of multiple cycles of radiant heat whole-bodyhyperthermia combined with carboplatin, Ifosfamide, eto-poside, and granulocyte colony stimulating factor, it wasfound that toxicity was minimized when carboplatin was
56 HYPERTHERMIA, SYSTEMIC
0.0
1.0
2.0
3.0
4.0
5.0
GEM+WBH schedule
TE
R fo
r tu
mo
r cu
res
GEM+WBH(0) GEM+WBH(+24) GEM+WBH(+48)
GEM+WBH(0 h) GEM+WBH(+24 h) GEM+WBH(+48 h)
0.06
2.983.57
Figure 4. Schedule dependence of fever range whole-bodyhyperthermia enhanced gemcitabine tumor cures. A supraaddi-tive cure rate occurred when whole-body hyperthermia (WBH)was given at the same time as gemcitabine administration or 48 hlater. When hyperthermia followed gemcitabine by 24 h the numberof cures droppedtoalmostzero, wellbelow thenumber achieved withgemcitabine alone.
given during the plateau phase of WBH, 10 min after targettemperature was reached (56).
A major rationale for whole-body hyperthermia in can-cer treatment is the ability to treat metastases, but this isactually a controversial issue. There have been no clinicalstudies specifically designed to study the effect of systemichyperthermia on either the efficacy against metastaticdisease or prevention of development of metastases.Increased survival in advanced malignancies is often inter-preted to mean a reduction in metastatic disease, but directmeasurement of the incidence and response of metastasesis rare. Based on some animal studies, it has been sug-gested that systemic hyperthermia could actually promotethe metastatic spread of tumor cells, but this has not beenconfirmed. One clinical study found an increase of tumorcells in blood 24 h after 41.8 8C WBH, but there was no
evidence that this caused metastatic spread of disease (57).Several animal experiments do support the efficacy ofwhole-body hyperthermia against metastases. In mousemodels of lung cancer and melanoma, the number of lungmetastases was scored after repeated systemic microwaveheating. It was found that the number of lung metastaseswas significantly reduced, and NK-cell activity was higher,in treated animals. The authors hypothesized that WBHinterferes with the spread of organ metastases, possiblythrough a mechanism involving NK cells (13). Anotherstudy of mouse Lewis lung carcinoma in which the animalswere treated with 60 min of systemic hyperthermia at42 8C, demonstrated a reduction in the number andpercentage of large metastases (>3 mm) on day 20 post-tumor implantation. Addition of radiation led to a reduc-tion to 50% of control of the number of lung metastases as
HYPERTHERMIA, SYSTEMIC 57
Table 6. Chemotherapy Agents Used with Whole-Body Hyperthermia
Class of AgentLikely Mechanismof Heat Interaction
Drugs Used withWBH in Clinical Studies
InvestigatorReferencesa
Alkylating agents Impaired DNA repair Cyclophosphamide (CTX) Parks, 1983 (4)Improved pharmacokinetics Engelhardt, 1988 (34)
Dacarbazine (DTIC) Lange, 1983 (35)Melphalan (L-PAM) Robins, 1997 (36)Ifosfamide (IFO) Engelhardt, 1988 (34)
Issels, 1990 (37)Westermann, 2003 (38)
Nitrosoureas Impaired DNA repair BCNU Parks, 1983 (4)Improved pharmacokinetics Bull, 1992 (39)
Me-CCNU Bull, 1992 (39)Platinum agents Impaired DNA repair Cisplatin (CDDP) Parks, 1983 (4)
Altered plasma protein binding Herman, 1982 (40)Engelhardt, 1990 (41)Robins, 1993 (42)Douwes, 2004 (43)
Carboplatin (CBDCA) Westermann, 2003 (38)Hegewisch-Becker, 2002 (44)Hegewisch-Becker, 2003 (45)Douwes, 2004 (43)Richel, 2004 (46)Strobl, 2004 (47)
Oxaliplatin Elias, 2004 (48)Hegewisch-Becker, 2002 (44)
Anthracyline antibiotics Impaired DNA repair Adriamycin Engelhardt, 1990 (41)Enzyme activation Bull, 2002 (49)
Bleomycin Herman, 1982 (40)Antimetabolites Increased drug transport 5-FU Lange, 1983 (35)
Cell cycle arrest Larkin, 1979 (50)Impaired DNA repair Bull, 2002 (49)
Hegewisch-Becker, 2002 (44)Gemcitabine Bull, 2004 (51)
Antiproliferatives Impaired DNA repair Etoposide (VP-16) Barlogie, 1979 (52)Issels, 1990 (37)Westermann, 2003 (42)
Topoisomerase inhibitors Impaired DNA repair Irinotecan (CPT-11) Hegewisch-Becker, 2003 (45)Elias, 2004 (48)
Taxanes Microtubule disruption Paclitacel Strobl, 2004 (49)Apoptosis Docetaxel Strobl, 2004 (49)
Biological responsemodifiers
Increased anti-viral andantiproliferative activity
Interferon Robins, 1989 (53)
Bull, 2002, 2004 (34,49)
aReferences prior to 1980, or not in English, are not provided in the Bibliography at the end of this article.
well as the percent of large metastases on day 20 (58). In abreast cancer ocult metastasis model in rats, 6 h of 40 8Cwhole-body hyperthermia combined with daily, low dose,metronomic irinotecan resulted in delayed onset, andreduced incidence, of axillary lymph node metastases com-pared to control in rats, as did treatment with 40 8C WBHalone. The combination therapy also reduced axillarymetastasis volume. Interestingly, none of the therapiessignificantly affected inguinal lymph node metastases,but lung metastases were decreased in both the combina-tion therapy and WBH alone groups. Rats treated withfever-range whole-body hyperthermia and metronomicirinotecan also survived significantly longer (36%) thancontrol animals (59).
Systemic Hyperthermia and Radiotherapy. The augmen-tation of ionizing radiation induced tumor kill byhyperthermia is well documented for local hyperthermiaand has led to numerous protocols combining whole-bodyhyperthermia with radiation therapy (60,61). Hyperther-mia is complementary to radiation in several regards:ionizing radiation acts predominantly in the M and G1
phases of the cell cycle while hyperthermia acts largelyin S phase; radiation is most effective in alkaline tissueswhereas hyperthermic cytotoxicity is enhanced underacidic conditions; radiation is not effective in hypoxicregions yet hyperthermia is most toxic to hypoxic cells.Thus when hyperthermia is combined with radiotherapy,both the hypoxic, low pH core of the tumor is treated as wellas the relatively well perfused outer layers of the tumor.Furthermore, because of its vascular effects, hyperthermiaenhances tumor oxygenation thus potentiating radiationcell kill. Hyperthermia also increases the production of oxy-gen radicals by radiation, and reduces the repair of DNAdamage caused by ionizing radiation. Thus hyperthermiaand radiotherapy together often have a synergistic effect,and this combination is now well accepted for treatment of anumber of tumors.
Fever-Range WBH. Like systemic hyperthermia alone,combined modality treatments were initially aimed toachieve maximally tolerated temperatures. Such regi-mens, however, carry significant risk to the patient,require general anesthesia, and necessitate experienced,specialist personnel to provide careful monitoring of vitalsigns and patient care during the treatment. Morerecently, it has been appreciated that lower core bodytemperatures (39–40 8C) maintained for a longer time(4–8 h), much like fever, can indirectly result in tumorregression through effects on tumor vasculature, theimmune response, and waste removal (detoxification).The optimum duration and frequency of mild hyperther-mia treatment has, however, not yet been determined.Protocols range from single treatments of 4–6 h, or similarlong duration treatments given once during each cycle ofchemotherapy, to daily treatments of only 1 h. Severalstudies of mild, fever-range, whole-body hyperthermiawith chemotherapy have demonstrated efficacy against abroad range of cancers (34,17) and clinical trials are cur-rently being conducted at the University of Texas HealthScience Center at Houston, Roswell Park Cancer Institute,
New York, and by the German Interdisciplinary WorkingGroup on Hyperthermia (62).
Systemic Hyperthermia and Metabolic Therapy.Increased rates of metabolic reactions lead to rapid turn-over of metabolites, causing cellular energy depletion,acidosis, and consequent metabolic disregulation. Tumors,which have increased metabolic rates [glucose, adenominetriphosphate (ATP)] compared to normal cells, may beparticularly sensitive to thermally induced energy deple-tion and this has been exploited in the Cancer MultistepTherapy developed by von Ardenne, which is a combinedhyperthermia–chemotherapy–metabolic therapy approachto cancer (63). The core of this approach is systemichyperthermia at 40–42 8C, sometimes with added localhyperthermia to achieve high temperatures within thetumor. A 10% solution of glucose is infused into the patientto achieve a high accumulation of lactic acid within thetumor that cannot be cleared because of sluggish blood flowand confers an increased sensitivity to heat to the tumorcells. Administration of oxygen increases the arterial oxy-gen pressure and stimulates lysozymal cytolysis. Finallylow dose chemotherapy is added.
Palliation. Pain relief is reported by many patientsreceiving systemic hyperthermia treatment, whether withchemotherapy or radiation. Indeed, almost all patientsundergoing thermoradiotherapy report pain relief.Immediate pain relief following treatment is likely to stemfrom an increased level of circulating b-endorphins, whilelonger term pain relief may be due to increased blood flow,direct neurological action, and disease resolution, forexample, tumor regression in cancer patients, or detoxifi-cation. Meaningful improvements in quality of life typi-cally result from such pain relief. Localized infraredtherapy using lamps radiating at 2–25 mm is used forthe treatment and relief of pain in numerous medicalinstitutes in China and Japan.
Diseases Other than Cancer. Therapeutic use of heatlamps emitting IR radiation is commonplace throughoutthe Orient for rheumatic, neurological and musculoskele-tal conditions, as well as skin diseases, wound healing, andburns. The improvements reported appear to be largelydue to increased blood flow bringing nutrients to areas ofischemia or blood vessel damage, and removing wasteproducts. Scientific reports of these treatments are, how-ever, difficult to find. Application of heat via hot baths orultrasound has long been standard in physical therapy forarthritis and musculoskeletal conditions, though ice packsare also used to counter inflammatory responses. Heatdecreases stiffness in tendons and ligaments, relaxes themuscles, decreases muscle spasm, and lessens pain. Unfor-tunately, few clinical trials of efficacy have been performed,and methodological differences or lack of rigor in thestudies hinder comparisons (64). A clinical trial inJapan reported a supposedly successful solution for sevenout of seven cases of rheumatoid arthritis treated withwhole-body IR therapy, and it is reported that the King ofBelgium was cured of his rheumatoid arthritis in threemonths due IR treatments. Systemic hyperthermia with
58 HYPERTHERMIA, SYSTEMIC
whole-body radiant heat units is being carried out inclinical centers as well as many private clinics in Germanyfor the purpose of alleviating rheumatoid arthritis. It hasbeen proposed that the induction of TNF receptors by WBHmay induce a remission in patients with active rheumatoidarthritis. The use of heat packs has long been standard torelieve the pain of fibromyalgia. Again, the therapeuticeffect is believed to be due to increased circulation flushingout toxins and speeding the healing process. Whole-bodyhyperthermia treatment for fibromyalgia and chronic fati-gue syndrome (CFS) is to be found in a number of privateclinics. Hyperthermia increases the number and activity ofwhite blood cells, stimulating the depressed immune sys-tem of the CFS patient.
Because of its immune stimulating effects, whole-bodyhyperthermia is a strong candidate for treatment of chronicprogressive viral infections, such as HIV and hepatitis C. Aclinical trial at the University Medical Center Utrecht, TheNetherlands has evaluated extracorporeal heating to inducesystemic hyperthermia of 41.8 8C for 120 min under propo-fol anesthesia for treatment of hepatitis C (65). Humanimmunodeficiency virus (HIV)-infected T cells are moresensitive to heat than healthy lymphocytes, and suscept-ibility increases when the cells are presensitized by expo-sure to tumor necrosis factor. Thus, induction of whole-bodyhyperthermia or hyperthermia specifically limited to tissueshaving a high viral load is a potential antiviral therapy foracquired immunodeficiency syndrome (AIDS). An Italianstudy has found treatment of AIDS with beta-carotene andhyperthermia to be synergistic, preventing progression ofearly disease and also increasing the survival time inpatients with severe AIDS. A single treatment of low flowextracorporeal hyperthermia was found effective againstAIDS associated Kaposi’s sarcoma, though there was sig-nificant toxicity. Core temperature was raised to 42 8C andheld for 1 h with extracorporeal perfusion and ex vivoblood heating to 49 8C. Complete or partial regressionswere seen in 20/29 of those treated at 30 days post-treat-ment, with regressions persisting in 14/29 of those treatedat 120 days post-treatment. At 360 days, 4/29 maintainedtumor regressions with 1 patient being in complete remis-sion still at 26 months (66).
THE FUTURE OF SYSTEMIC HYPERTHERMIA
While there is a resurgence of interest in systemichyperthermia, this modality has not yet been adopted asa mainstream therapy, and optimal clinical trials havenot yet been carried out. Well-designed, well-controlled,multicenter clinical trials need to be conducted. In order tounequivocally demonstrate the utility of whole-body hyper-thermia inthetreatmentofcanceraswellasotherdiseases, itwill be important to accrue a sufficiently large number ofpatients who do not have end-stage disease. Thanks to thecommercial availability of systemic hyperthermia systems,the variability between induction techniques at differentinstitutions can be removed. Newer instrumentation, parti-cularlynear-IR radiantheatdevices,alongwithtreatmentatlower temperatures (fever-range thermal therapy) shouldlead to significantly reduced toxicity. Better exploitation of
the narrow window of effective temperatures within whichthe cellular effects of heat can be exploited yet damageremains minimal, and improved understanding of the biolo-gical interactions invivoof systemicheatwithchemotherapyand radiation will be essential to optimize therapy.
The effects of systemic hyperthermia on tumor bloodflow and vascular permeability have the potential toincrease delivery of various small molecules, nanoparticles,and gene therapy vectors to tumors. Ferromagnetic nano-particles can be heated by external magnetic fields and offerthe potential for internal hyperthermia, both locally andsystemically. Thermally sensitive liposomes that releasetheir contents at designated temperatures are also of inter-est. The ability of systemic hyperthermia to aid in systemicdelivery of gene therapy vectors (the holy grail of genetherapy) and enhance transfection of cells with therapeuticgene plasmids is under investigation in several laboratories(67,68), and shows potential along with targeted gene ther-apy via the heat shock response. For example, Fig. 5 shows afourfold hyperthermic increase of therapeutic gene deliveryto tumor when plasmid DNA was injected intravenouslyinto mammary carcinoma bearing rats immediately after 6h of whole-body hyperthermia at 40 8C. Thus systemichyperthermia is likely to see increasing application as anenhancer of drug delivery.
There is a great deal of interest in the immunologicalconsequences of whole-body hyperthermia, and as theybecome better understood, the combination of systemichyperthermia with specific immunotherapies will undoubt-edly be pioneered, not just for cancer but also, by analogywith fever, in a broad range of diseases.
SUMMARY
Systemic hyperthermia is founded on solid physical andbiological principles and shows promise in the treatmentof a number of diseases. Modern whole-body hyperther-mia devices use IR-A radiation sources together witheffective heat loss techniques to achieve a controlled,uniform temperature distribution throughout the bodywith minimal patient toxicity. A shift in paradigm hasoccurred away from achieving direct cell killing with short
HYPERTHERMIA, SYSTEMIC 59
0
1
2
3
4
5
Liver Tumor
40˚C
/37˚
C r
atio
of
HS
Vtk
m
ole
cule
s p
er c
ell
grp78-HSVtk
Figure 5. Fever range whole-body hyperthermia increasestherapeutic gene (grp78-HSVtk) delivery in tumor.
bouts of maximally tolerated temperatures, to inducingindirect curative effects through longer duration treatmentsat lower temperatures, and synergy with other modalities,such as radiotherapy. Better understanding of the interac-tions of elevated temperature with metabolic and geneticpathways will allow thermally driven targeted therapies.Of particular promise is the use of systemic hyperthermiaas an immune system stimulator and adjunct to immu-notherapy. Application of systemic hyperthermia to nano-particle delivery and gene therapy is emerging. Whole-bodyhyperthermia is moving from being dubbed an alternativetherapy to becoming a standard treatment and clinicalhyperthermia centers are to be found all over the world.
Useful Websites
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6.section.40680
Techniques andDevices Usedto ProduceHyperthermia
http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.section.7813
Physics andPhysiology ofHeating
http://www.duke.edu/~dr3/hyperthermia_general.html
Clinical HyperthermiaBackground
http://www.eurekah.com/isbn.php?isbn=1-58706-248-8&bookid=143&catid=50
Online book:LocoregionalRadiofrequency-perfusionaland Whole BodyHyperthermia inCancer Treatment:New Clinical Aspects,E.F. Baronzio andA. Gramaglia (eds.),Eurekah BioscienceDatabase
http://www.esho.info/professionals/
European Society forHyperthermicOncology
http://www.hyperthermie.org/index2.html
GermanInterdisciplinaryWorking group onhyperthermia
http://www.uth.tmc.edu/thermaltherapy/
Systemic ThermalTherapy at theUniversity of Texas
BIBLIOGRAPHY
1. Nauts HC. Bacterial pyrogens: beneficial effects on cancerpatients. In: Gautherie M, Albert E, editors. Biomedical Ther-mology, Progress in Clinical Biological Research. New York:Alan R. Liss; 1982. p 687–696.
2. Law HT, Pettigrew RT. Heat transfer in whole bodyhyperthermia. Ann NY Acad Sci 1980;335:298–310.
3. Robins HI, et al. A non-toxic system for 41.8 8C whole bodyhyperthermia: results of a phase I study using a radiant heatdevice. Cancer Res 1985;45:3937–3944.
4. Parks LC, Smith GV. Systemic hyperthermia by extracorpor-eal induction techniques and results. In: Storm FK, editor.
Hyperthermia in Cancer Therapy. Boston: Hall; 1983.pp 407–446.
5. van der Zee J, van Rhoon GC, Faithfull NS, van den Berg AP.Clinical hyperthermic practice: whole body hyperthermia. In:Field SB, Hand JW, editors. An Introduction to the PracticalAspects of Clinical Hyperthermia. London: Taylor & Francis;1990.
6. Wust P, et al. Feasibility and analysis of thermal parametersfor the whole-body-hyperthermia system IRATHERM-2000.Int J Hyperthermia 2000 Jul–Aug; 16(4):325–339.
7. Blazickova S, Rovensky J, Koska J, Vigas M. Effect ofhyperthermic water bath on parameters of cellular immunity.Int J Clin Pharmacol Res 2000;20(1–2):41–46.
8. Vaupel P, Kallinowski F. Physiological effects of hyperthermia. In:Streffer C, editor. Hyperthermia and the Therapy of MalignantTumors. Berlin/Heidelberg, Germany: Springer-Verlag; 1987.
9. Dudar TE, Jain RK. Differential response of normal and tumormicrocirculation to hyperthermia. Cancer Res 1984;44(2):605–612.
10. Kong G, Braun RD, Dewhirst MW. Characterization of theeffect of hyperthermia on nanoparticle extravasation fromtumor vasculature. Cancer Res 2001;61:3027–3032.
11. Jain RK. Normalization of tumor vasculature: an emerging con-cept in antiangiogenic therapy. Science 2005;307(5706): 58–62.
12. Urano M, et al. Effect of whole body hyperthermia on cellsurvival, metastasis frequency, and host immunity in moder-ately and weakly immunogenic murine tumors. Cancer Res1983;43:1039–1043.
13. Shen RN, et al. Whole-body hyperthermia decreases lungmetastases in lung tumor-bearing mice, possibly via amechanism involving natural killer cells. J Clin Immunol1987;7(3):246–253.
14. Roigas J, Wallen ES, Loening SA, Moseley PL. Heat shockprotein (HSP72) surface expression enhances the lysis of ahuman renal cell carcinoma by IL-2 stimulated NK cells. AdvExp Med Biol 1998;451:225–229.
15. Burd R, et al. Tumor cell apoptosis, lymphocyte recruitmentand tumor vascular changes are induced by low temperature,long duration (fever-like) whole body hyperthermia. J CellPhysiol 1998;177(1):137–147.
16. Ostberg JR, Gellin C, Patel R, Repasky EA. Regulatory poten-tial of fever-range whole body hyperthermia on Langerhanscells and lymphocytes in an antigen-dependent cellularimmune response. J Immunol 2001;167(5):2666–2670.
17. Kraybill WG, et al. A phase I study of low temperature, longduration (fever-range) whole body hyperthermia (WBH) inpatients with advanced solid tumors: correlation with mousemodels. Int J Hyperthermia 2002;18:253–266.
18. Atanackovic D, et al. 41.8 degrees C whole body hyperthermiaas an adjunct to chemotherapy induces prolonged T cell acti-vation in patients with various malignant diseases. CancerImmunol Immunother Epub 2002 Oct 18 2002;51(11–12):603–613.
19. Barni S, et al. Lysosomal exocytosis induced by hyperthermia:a new model of cancer death. III. effect on liver metastasis.Biomed Pharmacother 1996;50:79–84.
20. Hou K. The level changes of peripheral blood PGE2 and clinicalsignificance in patients with malignant tumor before and afterwhole body hyperthermia. Proceedings of the 26th Congress ofthe International Clinical Hyperthermia Society, September9–12, 2004, Shenzhen, China, 2004; p 66.
21. Manjili MH, et al. Subjeck, Cancer immunotherapy: stressproteins and hyperthermia. Int J Hyperthermia 2002;18(6):506–520.
22. Ialenti A, et al. Inhibition of cyclooxygenase-2 gene expressionby the heat shock response in J774 murine macrophages. EurJ Pharmacol 2005;509(2–3):89–96.
60 HYPERTHERMIA, SYSTEMIC
23. Repasky EA, Issels R. Physiological consequences ofhyperthermia: Heat, heat shock proteins and the immuneresponse. Int J Hyperthermia 2002;18:486–489.
24. Ostberg JR, Repasky EA. Emerging evidence indicates thatphysiologically relevant thermal stress regulates dendritic cellfunction. Cancer Immunol Immunother [Epub ahead of print];Apr 28, 2005.
25. Berry JM, Michalsen A, Nagle V, Bull JM. The use of esmololin whole-body hyperthermia: cardiovascular effects. Int JHyperthermia 1997;13(3):261–268.
26. Robins HI, et al. Adjunctive therapy (whole body hyperther-mia versus Ionidamine) to total body irradiation for the treat-ment of favorable B-cell neoplasms: a report of two pilotclinical trials and laboratory investigations. Int J Radiat OncoBiophys 1990;18:909–920.
27. Ohno S, et al. Haematological toxicity of carboplatin andcisplatin combined with whole body hyperthermia in rats.Br J Cancer 1993;68:469–474.
28. Haveman J, et al. Effects of hyperthermia on the peripheralnervous system: a review. Int J Hyperthermia 2004;20(4):371–391.
29. Calvert AH, et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboylate platinum II. Cancer ChemotherPharmacol 1982;9:140–147.
30. Sapareto SA, Dewey WC. Thermal dose determination in cancertherapy. Int J Radiat Oncol Biol Phys 1984;10(6):787–800.
31. Thrall DE, et al. Using units of CEM 43 degrees C T90, localhyperthermia thermal dose can be delivered as prescribed. IntJ Hyperthermia 2000;16(5):415–428.
32. Webb AG. Temperature measurement using nuclear magneticresonance. Ann Reports NMR Spectrosc 2001;45:1–67.
33. Stafford RJ, Hazle JD, Glover GH. Monitoring of high-inten-sity focused ultrasound-induced temperature changes in vitrousing an interleaved spiral acquisition. Magn Reson Med2000;43(6):909–912.
34. Engelhardt R. Summary of recent clinical experience in whole-body hyperthermia combined with chemotherapy. RecentResults Cancer Res 1988;107:200–224.
35. Lange J, Zanker KS, Siewert JR, Eisler K, Landauer B, KolbE, Blumel G. and Remy, W. Extracorporeally induced whole-body hyperthermia in conventionally incurable malignanttumor patients Med Wochenschr. 1983;108(13):504–509.
36. Robins HI, et al. Phase I clinical trial of melphalan and 41.8degrees C whole-body hyperthermia in cancer patients. J ClinOncol 1997;15:158–164.
37. Issels RD, Wilmanns W, editors. Recent Results in CancerResearch, Vol. 107: Application of Hyperthermia in theTreatment of Cancer.Berlin/Heidelberg: Springer Verlag; 1988.
38. Westermann AM, et al. Systemic Hyperthermia OncologicWorking Group, A Systemic Hyperthermia Oncologic WorkingGroup trial, Ifosfamide, carboplatin, and etoposide combinedwith 41.8 degrees C whole-body hyperthermia for metastaticsoft tissue sarcoma. Oncology 2003;64(4):312–321.
39. Bull JM, et al. Chemotherapy resistant sarcoma treated withwhole body hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Int J Hyperthermia 1992;8(3):297–304.
40. Herman TS, Sweets CC, White DM, Gerner EW. Effectof heating on lethality due to hyperthermia and selectedchemotherapeutic drugs. J Natl Cancer Inst 1982;68(3):487–491.
41. Engelhardt R, et al. Treatment of disseminated malignantmelanoma with cisplatin in combination with whole-bodyhyperthermia and doxorubicin. Int J Hyperthermia 1990;6(3):511–515.
42. Robins HI, et al. Phase I clinical trial of carboplatin and 41.8degrees C whole-body hyperthermia in cancer patients. J ClinOncol 1993;11:1787–1794.
43. Douwes F, et al. Whole-body hyperthermia in combinationwith platinum-containing drugs in patients with recurrentovarian cancer. Int J Clin Oncol 2004;9(2):85–91.
44. Hegewisch-Becker S, et al. Whole-body hyperthermia(41.8 8C) combined with bimonthly oxaliplatin, high-dose leu-covorin and 5-fluorouracil 48-hour continuous infusion inpretreated metastatic colorectal cancer: a phase II study.Ann Onc 2002;13(8):1197–1204.
45. Hegewisch-Becker S, et al. Whole body hyperthermia (WBH,41.8 8C)combinedwithcarboplatinandetoposide inadvancedbiliarytract cancer. Proc Am Soc Clin Oncol 2003; (abstr. 1247), 22:311.
46. Richel O, et al. Phase II study of carboplatin and whole bodyhyperthermia (WBH) in recurrent and metastatic cervicalcancer. Gynecol Oncol 2004;95(3):680–685.
47. Strobl B, et al. Whole body hyperthermia combined with carbo-platin/paclitaxel in patients with ovarian carcinoma–Phase-II-study. J Clin Oncol -Proc Am Soc Clin Oncol 2004;22(14S).
48. Elias D, et al. Heated intra-operative intraperitoneal oxali-platin plus irinotecan after complete resection of peritonealcarcinomatosis: pharmacokinetics, tissue distribution and tol-erance. Ann Oncol 2004;15:1558–1565.
49. Bull JM, et al. Phase I study of long-duration, low-tempera-ture whole-body hyperthermia (LL-WBH) with liposomal dox-orubicin (Doxil), 5-fluorouracil (5-FU), & interferon-a (IFN-a),Proc Amer. Soc Clin Oncol 2002;(Abst. 2126).
50. Larkin JM, A clinical investigation of total-body hyperthermiaas cancer therapy. Cancer Res, 1979;39(6 Pt 2):2252–2254.
51. Bull JM, et al. Update of a phase I clinical trial using fever-range whole-body hyperthermia (FR-WBH) þ cisplatin (CIS) þgemcitabine (GEM) þ metronomic, low-dose interferon-alpha(IFN-alpha), Proceedings of the International Congress onHyperthermic Oncology, 20.-24.04., St. Louis, (Session 21and Poster 689); 2004.
52. Barlogie B, Corry PM, Lip E, Lippman L, Johnston DA,Tenczynski TF, Reilly E, Lawson R, Dosik G, Rigor B,Hankenson R, Freireich EJ Total-body hyperthermia withand without chemotherapy for advanced human neoplasms.Cancer Res 1979;39(5):1481–1489.
53. Robins HI, et al. Phase I trial of human lymphoblastoidinterferon with whole body hyperthermia in advanced cancer.Cancer Res 1989;49(6):1609–1615.
54. Gerad H, van Echo DA, Whitacre M, Ashman M, Helrich M, FoyJ, Ostrow S, Wiernik PH, Aisner J. Doxorubicin, cyclophospha-mide, and whole body hyperthermia for treatment of advancedsoft tissue sarcoma. Cancer. 1984 Jun 15;53(12):2585–91.
55. Baba H, et al. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermiatherapy by optimal heat/drug scheduling. Cancer Res1989;49(24 Pt. 1):7041–7044.
56. Katschinski DM, et al. Optimization of chemotherapy admin-istration for clinical 41.8 degrees C whole body hyperthermia.Cancer Lett 1997;115(2):195–199.
57. Hegewisch-Becker S, et al. Effects of whole body hyperthermia(41.8 degrees C) on the frequency of tumor cells in the per-ipheral blood of patients with advanced malignancies. ClinCancer Res 2003;9(6):2079–2084.
58. Teicher BA, Holden SA, Ara G, Menon K. Whole-bodyhyperthermia and lonidamine as adjuvant therapy to treat-ment with cisplatin with or without local radiation in mousebearing the Lewis lung carcinoma. Int J Hyperthermia1995;11(5):637–645.
59. Sumiyoshi K, Strebel FR, Rowe RW, Bull JM. The effectof whole-body hyperthermia combined with ‘metronomic’ che-motherapy on rat mammary adenocarcinoma metastases. IntJ Hyperthermia 2003;19(2):103–118.
60. Overgaard J, et al. Randomised trial of hyperthermiaas adjuvant to radiotherapy for recurrent or metastatic
HYPERTHERMIA, SYSTEMIC 61
malignant melanoma, European Society for HyperthermicOncology. Lancet 1995;345(8949):540–543.
61. Hehr T, Wust P, Bamberg M, Budach W. Current and poten-tial role of thermoradiotherapy for solid tumours. Onkologie2003;26(3):295–302.
62. Hildebrandt B, et al. Current status of radiant whole-bodyhyperthermia at temperatures > 41.5 degrees C and practicalguidelines for the treatment of adults. The German Interdis-ciplinary Working Group on Hyperthermia. Int J Hyperther-mia 2005;21(2):169–183.
63. Hildebrandt B, et al. Whole-body hyperthermia in the scope ofvon Ardenne’s systemic cancer multistep therapy (sCMT)combined with chemotherapy in patients with metastaticcolorectal cancer: a phase I/II study. Int J Hyperthermia2004;20(3):317–333.
64. Robinson V, et al. Thermotherapy for treating rheumatoidarthritis. Cochrane Database Syst Rev 1: CD002826; 2002.
65. van Soest H, van Hattum J. New treatment options for chronichepatitis C. Adv Exp Med Biol 2003;531:219–226.
66. Pontiggia P, Rotella GB, Sabato A, Curto FD. Therapeutichyperthermia in cancer and AIDS: an updated survey. JEnviron Pathol Toxicol Oncol 1996;15(2–4):289–297.
67. Li CY, Dewhirst MW. Hyperthermia-regulated immunogenetherapy. Int J Hyperthermia 2002;18(6):586–596.
68. Okita A, et al. Efficiency of lipofection combined with hyperther-mia in Lewis lung carcinoma cells and a rodent pleural dissemi-nation model of lung carcinoma. Oncol Rep 2004;11:1313–1318.
Further Reading
Bakhshandeh A, et al. Year 2000 guidelines for clinical practice ofwhole body hyperthermia combined with cytotoxic drugs fromthe University of Lubeck and the University of Wisconsin. JOncol Pharm Practice 1999;5(3):131–134.
Field SB, Hand JW, editors. An Introduction to the Practical Aspectsof Clinical Hyperthermia. London: Taylor & Francis; 1990.
Gautherie M, editor. Methods of External Hyperthermic Heating.Berlin/Heidelberg: Springer Verlag; 1990.
Gautherie M, editor. Whole Body Hyperthermia: Biological andClinical Aspects. Berlin/Heidelberg: Springer Verlag; 1992.
Hahn GM. Hyperthermia and Cancer. New York: Plenum Press, 1982.Hildebrandt B, et al. Current status of radiant whole-body
hyperthermia at temperatures > 41.5 degrees C and practicalguidelines for the treatment of adults. The German Interdisci-plinary Working Group on Hyperthermia. Int J Hyperthermia2005;21(2):169–183.
Issels RD, Wilmanns W, editors. Recent Results in CancerResearch, Vol. 107: Application of Hyperthermia in theTreatment of Cancer. Berlin/Heidelberg: Springer Verlag;1988.
Nussbaum GH, editor. Physical Aspects of Hyperthermia. AmericanAssociationofPhysicists inMedicineMedicalPhysicsMonographNo. 8. New York: American Institute of Physics; 1982.
Guan J, et al. The clinical study of whole-body hyperthermia(WBH) improving the survival state of patients with advancedcancer. Proc 26th Congress of the International ClinicalHyperthermia Society, Sept. 9–12, 2004, Shenzhen, China;2004; p 66.
Kurpeshev OK, Tsyb AF, Mardynsky YS. Whole-body hyperthermiafor treatment of patients with disseminated tumors- Phase II. In:P.H. Rehak, K.H. Tscheliessnigg, editors. Proceedings 22nd.Annual Meeting of the European Society for HyperthermicOncology, June 8–11, 2005, Graz, Austria, 2005; p 103.
Hou K. Assessment of the effects and clinical safety of the treat-ment of advanced malignant tumor with extracorporeal wholebody hyperthermia. Proceedings of the 26th Congress of the
International Clinical Hyperthermia Society, Sept. 9–12, 2004,Shenzhen, China; 2004 p 71.
See also BIOHEAT TRANSFER; HEAT AND COLD, THERAPEUTIC; HYPERTHER-
MIA, INTERSTITIAL; HYPERTHERMIA, ULTRASONIC; RADIATION DOSIMETRY FOR
ONCOLOGY.
62